Page 39 - Vitro Diagnostics News Today

Share this article Share this article ResearchAndMarkets.coms offering. The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%. The growth in the cardiac marker testing market is majorly driven by the growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the ident...

WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing 29 January 2021 Reading time: To address the lack of access to tests and testing services in multiple countries, WHO since 2018 has published a yearly essential diagnostics list (EDL), a basket of recommended in vitro diagnostics that should be available at point-of-care and in...

Share this article Share this article ResearchAndMarkets.coms offering. Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different wa...

The U.S. new cases 7-day rolling average are 17.3 % LOWER than the 7-day rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 8.6 % LOWER than the rolling average one week ago. U.S. deaths due to coronavirus are now 11.8 % HIGHER than the rolling average one week ago. Todays posts include: U.S. Coronavirus New Cases are 146,640 U.S. Coronavirus hospitalizations are at an elevated 108,957 U.S. Coronavirus deaths are at an elevated 4,087 U.S. Coronavirus immunizations hav...

Copy shortlink: The U.S. Food and Drug Administration is alerting lab managers that several COVID-19 tests, including one used in Minnesotas free public testing, carry a slight risk of returning inaccurate results because of recent genetic mutations in the virus. But theres an upside. Thermo Fisher Scientific, which makes the TaqPath COVID test used at community testing sites across the state, says the test not only remains accurate, but it may offer an important clue th...

Share: Jianshun Biosciences Co., Ltd. ("JS Bio") recently announced its strategic partnership with Etta Biotech Co., Ltd. ("Etta Biotech"), to set up a high titer transient protein expression platform for high quality protein production using JS Bios transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotechs transient transfection high titer protein expression platform. Dr. Edward Dai, Chairman and CEO of Etta Biotech (left); Dr. Luo Shun, Chairman and Pr...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors Celyad Oncology SEJanuary 11, 2021 GMT MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., ...

NDA Partners Awarded Government Contract to Conduct Reviews of EUAs for Laboratory Developed Tests for COVID-19 Share Article NDA Partners President, Earle Martin, announced today that the company has been awarded a contract with the US Department of Health & Human Services to conduct technical and regulatory reviews of applications for Emergency Use Authorizations (EUAs) submitted for laboratory developed tests for COVID-19. We are honored to have been selected to play a role in the support of...

Celyad Oncology SA: Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. "I am very pleased to welcome Marina to our Board of Directors," stated Filippo Petti, CEO of Celyad Oncology. "As a...

Dive Brief: FDA on Wednesday said it is working with SARS-CoV-2 test developers to determine potential impact on the efficacy of coronavirus diagnostics as a coronavirus variant first identified in the U.K. has now been found in the U.S. Tim Stenzel, director of the FDA’s Office of In Vitro Diagnostics and Radiological Health, told Wednesdays virtual town hall for test developers the agency is trying to assess whether existing coronavirus tests are able to properly detect new COVID-19 variant...